Literature DB >> 9385296

Update on rifampin drug interactions, III.

V A Strayhorn1, A M Baciewicz, T H Self.   

Abstract

Rifampin is a potent inducer of cytochrome P-450 oxidative enzymes. Examples of well-documented, clinically significant interactions include warfarin, oral contraceptives, cyclosporine, glucocorticoids, ketoconazole, theophylline, quinidine, digitoxin, and verapamil. Recent reports have demonstrated clinically relevant interactions with protease inhibitors, zidovudine, delavirdine, itraconazole, nifedipine, midazolam or triazolam, nortriptyline, and doxycycline. To avoid reduced therapeutic response, therapeutic failure, or toxic reactions when rifampin is added to or discontinued from medication regimens, clinicians need to be cognizant of these interactions. Enhanced knowledge of known interactions will continue to develop, including research on induction of specific cytochrome P-450 isoenzymes. New rifampin interactions will be discovered with further investigations.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9385296

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  13 in total

Review 1.  [Cytochrom-P450 mediated drug interactions caused by antibiotics].

Authors:  Christiane Thallinger; Christian Joukhadar
Journal:  Wien Med Wochenschr       Date:  2006-09

Review 2.  Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials.

Authors:  W J Burman; K Gallicano; C Peloquin
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

3.  Induction of hepatic and presystemic metabolism of antipyrine in the mice: rifampicin versus rifabutin.

Authors:  X G Liu; P K Narang; R C Li
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2001 Oct-Dec       Impact factor: 2.441

4.  Pharmacokinetic Interaction between amprenavir and rifabutin or rifampin in healthy males.

Authors:  R E Polk; D F Brophy; D S Israel; R Patron; B M Sadler; G E Chittick; W T Symonds; Y Lou; D Kristoff; D S Stein
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

5.  Disseminated mycotic infection caused by Colletotrichum acutatum in a Kemp's ridley sea turtle (Lepidochelys kempi).

Authors:  Charles A Manire; Howard L Rhinehart; Deanna A Sutton; Elizabeth H Thompson; Michael G Rinaldi; John D Buck; Elliott Jacobson
Journal:  J Clin Microbiol       Date:  2002-11       Impact factor: 5.948

Review 6.  Clinically significant interactions with drugs used in the treatment of tuberculosis.

Authors:  W W Yew
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

7.  Effect of rifampicin on the pharmacokinetics and pharmacodynamics of glimepiride.

Authors:  M Niemi; K T Kivistö; J T Backman; P J Neuvonen
Journal:  Br J Clin Pharmacol       Date:  2000-12       Impact factor: 4.335

8.  The effect of rifampin treatment on intestinal expression of human MRP transporters.

Authors:  M F Fromm; H M Kauffmann; P Fritz; O Burk; H K Kroemer; R W Warzok; M Eichelbaum; W Siegmund; D Schrenk
Journal:  Am J Pathol       Date:  2000-11       Impact factor: 4.307

9.  Safety, efficacy and pharmacokinetics of ritonavir 400mg/saquinavir 400mg twice daily plus rifampicin combined therapy in HIV patients with tuberculosis.

Authors:  Valeria Cavalcanti Rolla; Maria A da Silva Vieira; Douglas Pereira Pinto; Maria C Lourenço; Carlos da Silva de Jesus; Mariza Gonçalves Morgado; Milton Ferreira Filho; Eduardo Werneck-Barroso
Journal:  Clin Drug Investig       Date:  2006       Impact factor: 2.859

Review 10.  Pharmacokinetic aspects of treating infections in the intensive care unit: focus on drug interactions.

Authors:  F Pea; M Furlanut
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 5.577

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.